RUBIUS THERAPEUTICS, INC.

(RUBY)
  Report
Delayed Nasdaq  -  04:00 2022-08-15 pm EDT
0.8090 USD   +1.14%
08/12RUBIUS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers (form 8-K)
AQ
08/12Rubius Therapeutics, Inc. Announces Resignation of Natalie Holles as Member of the Board of Directors
CI
08/10Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/09/2022 08/10/2022 08/11/2022 08/12/2022 08/15/2022 Date
0.8(c) 0.7893(c) 0.7581(c) 0.7999(c) 0.809(c) Last
321 198 348 294 363 422 254 996 367 937 Volume
+0.90% -1.34% -3.95% +5.51% +1.14% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -188 M - -
Net cash position 2022 116 M - -
P/E ratio 2022 -0,43x
Yield 2022 -
Sales 2023 3,38 M - -
Net income 2023 -216 M - -
Net cash position 2023 100 M - -
P/E ratio 2023 -0,41x
Yield 2023 -
Capitalization 73,1 M 73,1 M -
EV / Sales 2022 -
EV / Sales 2023 -8,01x
Nbr of Employees 213
Free-Float 93,4%
More Financials
Company
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as... 
More about the company
Ratings of Rubius Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about RUBIUS THERAPEUTICS, INC.
08/12RUBIUS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
AQ
08/12Rubius Therapeutics, Inc. Announces Resignation of Natalie Holles as Member of the Boar..
CI
08/10Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business..
AQ
08/09RUBIUS THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Provides Business ..
PU
08/09RUBIUS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/09Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business..
GL
08/09Rubius Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/01RUBIUS THERAPEUTICS : Delisting/Failure to Satisfy Listing Rule/Transfer of Listing - Form..
PU
08/01RUBIUS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
AQ
07/26Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
GL
07/26Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
AQ
07/19RUBIUS THERAPEUTICS : Initial Statement of Beneficial Ownership (Form 3)
PU
07/19HotSpot Therapeutics Appoints Jose Carmona to Board of Directors
PR
07/14RUBIUS THERAPEUTICS : Appoints Susanne Schaffert, Ph.D., to its Board of Directors - Form ..
PU
07/14RUBIUS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Discl..
AQ
More news
News in other languages on RUBIUS THERAPEUTICS, INC.
08/12Rubius Therapeutics, Inc. annonce la démission de Natalie Holles en tant que membre du ..
08/09Rubius Therapeutics, Inc. annonce ses résultats pour le deuxième trimestre et le semest..
07/14Rubius Therapeutics, Inc. nomme Susanne Schaffert à son conseil d'administration
06/09Rubius Therapeutics dépose un prospectus mixte de 250 millions de dollars
05/24Rubius Therapeutics nomme Noubar Afeyan président du conseil d'administration ; les act..
More news
Analyst Recommendations on RUBIUS THERAPEUTICS, INC.
More recommendations
Chart RUBIUS THERAPEUTICS, INC.
Duration : Period :
Rubius Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RUBIUS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 0,81 $
Average target price 6,80 $
Spread / Average Target 741%
EPS Revisions
Managers and Directors
Pablo J. Cagnoni Chief Executive Officer & Director
Jose Carmona Chief Financial Officer
Noubar B. Afeyan Chairman
Spencer Fisk Senior Vice President-Manufacturing
Laurence Turka Chief Scientific Officer & Head-Research
Sector and Competitors
1st jan.Capi. (M$)
RUBIUS THERAPEUTICS, INC.-91.64%73
GILEAD SCIENCES, INC.-8.81%82 985
VERTEX PHARMACEUTICALS39.13%78 356
REGENERON PHARMACEUTICALS, INC.1.86%68 773
WUXI APPTEC CO., LTD.-20.33%40 492
BIONTECH SE-36.97%39 486